# A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

> **NCT07643766** · PHASE2 · RECRUITING · sponsor: **Enveda Therapeutics** · enrollment: 200 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** ENV-294
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07643766
- **Lead sponsor:** Enveda Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-29
- **Primary completion:** 2027-12
- **Final completion:** 2028-05
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07643766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07643766, "A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07643766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*